Publications
5674 Results
- Journal / Conference
- PLOS ONE 2015 May 8;10(5):e0126672
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID25955319
- PMC
- PMC4425512
- Study Number(s)
- SWOG-9217
Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial
- Journal / Conference
- Journal of Surgical Oncology Jun;111(7):923-928
- Year
- 2015
- Research Committee(s)
- Genitourinary
- PMID
- PMID25873574
- PMC
- PMC4602027
- Study Number(s)
- 4B951
Variability in surgical quality in a phase III prospective clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder
- Journal / Conference
- Journal of Clinical Oncology 33 (suppl 3; abstr TPS790); ASCO GI Cancers Symposium (January 15-17, 2015, in San Francisco, CA), TIPS poster;
- Year
- 2015
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1406
S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC)
- Journal / Conference
- Journal of Clinical Oncology 33(2):149-155
- Year
- 2015
- Research Committee(s)
- Breast
- PMID
- PMID25332254
- PMC
- PMC4279234
- Study Number(s)
- S1007
Tumor marker usage and medical care costs among older early-stage breast cancer survivors
- Journal / Conference
- British Journal of Haematology Nov;171(4):530-538
- Year
- 2015
- Research Committee(s)
- Lymphoma
- PMID
- PMID26343802
- PMC
- PMC4881845
- Study Number(s)
- E2496
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
- Journal / Conference
- Journal of Clinical Oncology 33 (suppl 7; abstr 152);ASCO GU Cancers Sympos (February 26-28, 2015, Orlando, FL), poster;
- Year
- 2015
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1014
Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014
- Journal / Conference
- Prostate Cancer and Prostatic Diseases, Sep;18(3):264-269
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID25939516
- PMC
- PMC4537352
- Study Number(s)
- SWOG-9217
Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng/mL, normal DRE, and negative for prostate cancer
- Journal / Conference
- Cancer, Jul 1;121(13):2193-2197
- Year
- 2015
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID25827820
- PMC
- PMC4589423
- Study Number(s)
- S1005
A phase II study of MK-2206, an allosteric inhibitor of AKT as second line therapy for advanced gastric and gastroesophageal junction cancer, a SWOG cooperative group trial (S1005)
- Journal / Conference
- Journal of Clinical Oncology 33 (suppl 7; abstr 403); ASCO GU Cancers Symposium (February 26-28, 2015, Orlando, FL), general poster session;
- Year
- 2015
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/E2805
Results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial
- Journal / Conference
- Experimental Biology 2015 Conference (March 28-April 1, 2015, Boston, MA), oral presentation, abst. #406.2;
- Year
- 2015
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217